Skip to main content
OpenTrials
Completed

NCT Number: NCT00102713

A Study for Treatment of Partial Seizures in Children

The purpose of the study is to assess the safety profile of the investigational medication, Depakote Sprinkle Capsules, in the treatment of partial seizures in children ages 3-10.

Completed

Looking for future studies?

Notify Me

Key information

Age range

3 year–10 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Neurology Clinic, P.C., Northport, Alabama, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Subject has diagnosis of partial seizures with/without secondary generalization, supported by:

  • Observed ictal events consistent with partial seizures with/without secondary generalization; Documented by reliable observers
  • 1 of following 3:
  • EEG at some time in past demonstrating focal abnormalities consistent with partial seizures
  • If the EEG is inconclusive or does not support partial seizures, then an MRI/CT will be done
  • If the MRI/CT fails to support a diagnosis of partial seizures, the subject may still qualify based on the principal Investigator's clinical diagnosis
  • Subject weighs at least 15 kg (33 lbs).
  • Parent/caregiver is able to keep an accurate seizure diary.

Exclusion criteria

  • Has had status epilepticus in the past 3 months prior to Screening
  • Has a history of any of: Cardiac (including clinically important abnormality on ECG); Renal; Psychiatric (including psychosurgery); Oncologic; Endocrine; Metabolic; Pancreatic; Hepatic disease (including clinical/serological history of hepatitis); Urea cycle disorder
  • Has: Expanding CNS neoplasm; Active CNS infection; Demyelinating disease; Degenerative neurological disease; Progressive encephalopathy; or any Progressive CNS disease
  • Has platelet count less than or equal to 100,000/mcL
  • Has blood chemistry ALT/AST value(s) greater than or equal to 2 times upper limit of normal at screening
  • Requires anticoagulant drug therapy
  • Receiving systemic chemotherapy
  • Requires treatment with aspirin
  • Subject is pregnant
  • Has been on ketogenic diet within 30 days prior to screening
  • Considered by investigator to be non-responder to valproate for treatment of epilepsy (e.g., Despite adequate trial with serum concentrations of 60 mcg/mL or greater, subject continues to have inadequate seizure control)

Treatment and study plan

Divalproex Sodium (Depakote Sprinkle Capsules)

Drug

Primary outcomes

  1. Partial Seizure Rate at Week 4

Secondary outcomes

  1. Adverse Events

  2. WASI

  3. WPPSI-III

  4. BASC

  5. UKU-Neurologic Assessment

  6. Vital Signs

  7. Clinical Laboratory Assessments

  8. ECG

  9. PK analysis

Sponsors and collaborators

Lead sponsor

Abbott

Industry

Registry information

Official study title

An Open Label Study for Treatment of Partial Seizures in Children

Important dates

Study start
2005
First posted
Feb 2, 2005
Registry last updated
May 21, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.